Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.

Louie T, Ribble W, Boccumini L, Johnson K, De Groote MA, Day J, Mason C, Sun X, Freeman J, Gu K, Tillotson G, Wilcox MH, Janjic N, Jarvis TC, Nayak SU, Ochsner UA, Bruss JB.

Open source

DOI
10.1016/s1473-3099(25)00721-2
Published
2026-01-22
Container
Lancet Infect Dis
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-25-00721-2,
  title = {Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.},
  author = {Louie T and  Ribble W and  Boccumini L and  Johnson K and  De Groote MA and  Day J and  Mason C and  Sun X and  Freeman J and  Gu K and  Tillotson G and  Wilcox MH and  Janjic N and  Jarvis TC and  Nayak SU and  Ochsner UA and  Bruss JB.},
  year = {2026},
  journal = {Lancet Infect Dis},
  doi = {10.1016/s1473-3099(25)00721-2},
  url = {https://doi.org/10.1016/s1473-3099(25)00721-2}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.
AU  - Louie T
AU  -  Ribble W
AU  -  Boccumini L
AU  -  Johnson K
AU  -  De Groote MA
AU  -  Day J
AU  -  Mason C
AU  -  Sun X
AU  -  Freeman J
AU  -  Gu K
AU  -  Tillotson G
AU  -  Wilcox MH
AU  -  Janjic N
AU  -  Jarvis TC
AU  -  Nayak SU
AU  -  Ochsner UA
AU  -  Bruss JB.
PY  - 2026
JO  - Lancet Infect Dis
DO  - 10.1016/s1473-3099(25)00721-2
UR  - https://doi.org/10.1016/s1473-3099(25)00721-2
ER  - 

APA

T, L., W, R., L, B., K, J., MA, D. G., J, D., C, M., X, S., J, F., K, G., G, T., MH, W., N, J., TC, J., SU, N., UA, O., & JB., B. (2026). Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.. Lancet Infect Dis. https://doi.org/10.1016/s1473-3099(25)00721-2

Source records